Adherence and resource use among patients treated with biologic drugs: findings from BEETLE study

References

• ZinkABraunJListingJWollenhauptJDisability and handicap in rheumatoid arthritis and ankylosing spondylitis – results from the German rheumatological database. German Collaborative Arthritis CentersJ Rheumatol200027361362210743798
   PubMed Web of Science ®Google Scholar
• BormanPToyGGBabaoğluSBodurHCilizDAlliNA comparative evaluation of quality of life and life satisfaction in patients with psoriatic and rheumatoid arthritisClin Rheumatol200726333033416622591
   PubMed Web of Science ®Google Scholar
• BüschKLudvigssonJFEkström-SmedbyKEkbomAAsklingJNeoviusMNationwide prevalence of inflammatory bowel disease in Sweden: a population-based register studyAliment Pharmacol Ther2014391576824127738
   PubMed Web of Science ®Google Scholar
• SpectorTDRheumatoid arthritisRheum Dis Clin North Am19901635135372217956
   PubMed Web of Science ®Google Scholar
• LebwohlMPsoriasisLancet200336193641197120412686053
   PubMed Web of Science ®Google Scholar
• SieperJBraunJNew treatment options in ankylosing spondylitis: a role for anti-TNFalpha therapyAnn Rheum Dis200160Suppl 3iii58iii6111890656
   PubMed Web of Science ®Google Scholar
• JacobsPBissonnetteRGuentherLCSocioeconomic burden of immune-mediated inflammatory diseases – focusing on work productivity and disabilityJ Rheumatol Suppl201188556122045980
   PubMedGoogle Scholar
• ScottDLKingsleyGHTumor necrosis factor inhibitors for rheumatoid arthritisN Engl J Med2006355770471216914706
   PubMed Web of Science ®Google Scholar
• Humira (adalimumab) prescribing informationEuropean Medicines Agency Available at: http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000481/human_med_000822.jsp&mid=WC0b01ac058001d124Accessed June 28, 2014
   Google Scholar
• Enbrel (etanercept) prescribing informationEuropean Medicines Agency Available at: http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000262/human_med_000764.jsp&mid=WC0b01ac058001d124Accessed June 28, 2014
   Google Scholar
• Remicade (infliximab) prescribing informationEuropean Medicines Agency Available at: http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000240/human_med_001023.jsp&mid=WC0b01ac058001d124Accessed June 28, 2014
   Google Scholar
• HyrichKLLuntMWatsonKDSymmonsDPSilmanAJBritish Society for Rheumatology Biologics RegisterOutcomes after switching from one anti-tumor necrosis factor alpha agent to a second anti-tumor necrosis factor alpha agent in patients with rheumatoid arthritis: results from a large UK national cohort studyArthritis Rheum2007561132017195186
   PubMed Web of Science ®Google Scholar
• PetersonAMNauDPCramerJABennerJGwadry-SridharFNicholMA checklist for medication compliance and persistence studies using retrospective databasesValue Health200710131217261111
   PubMed Web of Science ®Google Scholar
• BlumMAKooDDoshiJAMeasurement and rates of persistence with and adherence to biologics for rheumatoid arthritis: a systematic reviewClin Ther201133790191321715007
   PubMed Web of Science ®Google Scholar
• MarkensonJAGibofskyAPalmerWRPersistence with anti-tumor necrosis factor therapies in patients with rheumatoid arthritis: observations from the RADIUS registryJ Rheumatol20113871273128121572150
   PubMed Web of Science ®Google Scholar
• CramerJASilvermanSPersistence with bisphosphonate treatment for osteoporosis: finding the root of the problemAm J Med20061194 Suppl 1S12S1716563936
   PubMed Web of Science ®Google Scholar
• World Health OrganizationAdherence to Long-Term Therapies: Evidence for ActionGenevaWorld Health Organization2003
   Google Scholar
• HughesDCowellWKonczTCramerJInternational Society for Pharmacoeconomics and Outcomes Research Economics of Medication Compliance Working GroupMethods for integrating medication compliance and persistence in pharmacoeconomic evaluationsValue Health200710649850917970932
   PubMed Web of Science ®Google Scholar
• CramerJARoyABurrellAMedication compliance and persistence: terminology and definitionsValue Health2008111444718237359
   PubMed Web of Science ®Google Scholar
• Di BariMBalziDRobertsATPrognostic stratification of older persons based on simple administrative data: development and validation of the “Silver Code,” to be used in emergency department triageJ Gerontol A Biol Sci Med Sci201065215916419349591
   PubMed Web of Science ®Google Scholar
• Ministry of Labour, Health and Social PoliciesAnnual report on the hospitalization activity2005 Available from: http://www.ministerosalute.it/programmazione/sdo/sezDocumenti.jsp?id=148&label=ospAccessed June 28, 2014
   Google Scholar
• GonnellaJSLouisDZGozumMVECallahanCABarnesCADisease Staging Clinical and Coded Criteria. Version 5.26Ann Arbor, MIThomson Reuters2009
   Google Scholar
• TangBRahmanMWatersHCCallegariPTreatment persistence with adalimumab, etanercept, or infliximab in combination with methotrexate and the effects on health care costs in patients with rheumatoid arthritisClin Ther20083071375138418691998
   PubMed Web of Science ®Google Scholar
• CatalanVSLeLorierJPredictors of long-term persistence on statins in a subsidized clinical populationValue Health20003641742616464201
   PubMedGoogle Scholar
• ClaxtonAJCramerJPierceCA systematic review of the associations between dose regimens and medication complianceClin Ther20012381296131011558866
   PubMed Web of Science ®Google Scholar
• BartonJLPatient preferences and satisfaction in the treatment of rheumatoid arthritis with biologic therapyPatient Prefer Adherence2009333534420016797
   PubMed Web of Science ®Google Scholar
• HarleyCRFrytakJRTandonNTreatment compliance and dosage administration among rheumatoid arthritis patients receiving infliximab, etanercept, or methotrexateAm J Manag Care20039Suppl 6S136S14314577718
   PubMed Web of Science ®Google Scholar
• PunziLMatucci CerinicMCantiniFTreatment patterns of anti-TNF agents in Italy: an observational studyReumatismo2011631182821509346
   PubMedGoogle Scholar
• WilliamsAManiasEWalkerRInterventions to improve medication adherence in people with multiple chronic conditions: a systematic reviewJ Adv Nurs200863213214318537843
   PubMed Web of Science ®Google Scholar
• YaziciYKrasnokutskySBarnesJPHinesPLWangJRosenblattLChanging patterns of tumor necrosis factor inhibitor use in 9074 patients with rheumatoid arthritisJ Rheumatol200936590791319332636
   PubMed Web of Science ®Google Scholar
• OeiHBHookerRSCipherDJReimoldAHigh rates of stopping or switching biological medications in veterans with rheumatoid arthritisClin Exp Rheumatol200927692693420149307
   PubMed Web of Science ®Google Scholar
• BlomMKievitWFransenJThe reason for discontinuation of the first tumor necrosis factor (TNF) blocking agent does not influence the effect of a second TNF blocking agent in patients with rheumatoid arthritisJ Rheumatol200936102171217719723902
   PubMed Web of Science ®Google Scholar
• FidderHHSingendonkMMvan der HaveMOldenburgBvan OijenMGLow rates of adherence for tumor necrosis factor-α inhibitors in Crohn’s disease and rheumatoid arthritis: results of a systematic reviewWorld J Gastroenterol201319274344435023885145
   PubMed Web of Science ®Google Scholar
• Du PanSMDehlerSCiureaAZiswilerHRGabayCFinckhASwiss Clinical Quality Management PhysiciansComparison of drug retention rates and causes of drug discontinuation between anti-tumor necrosis factor agents in rheumatoid arthritisArthritis Rheum200961556056819405000
   PubMed Web of Science ®Google Scholar
• EspositoMGisondiPCassanoNSurvival rate of antitumour necrosis factor-α treatments for psoriasis in routine dermatological practice: a multicentre observational studyBr J Dermatol2013169366667223647206
   PubMed Web of Science ®Google Scholar
• SchwartzmanSMorganGJDoes route of administration affect the outcome of TNF antagonist therapy?Arthritis Res Ther20046Suppl 2S19S2315228617
   PubMed Web of Science ®Google Scholar